• 1
    Niederhuber JE, Brennan MD, Menck HR. The national cancer data base report on pancreatic cancer. Cancer 1995;76: 16717.
  • 2
    Douglass HO. Current approaches to multimodality management of advanced pancreatic cancer. Hepatogastroenterology 1993;40: 43342.
  • 3
    Calabresi P, Chabner BA. Chemotherapy of neoplastic disease. In: HardmanJG, LimbirdLH, MolinoffPB, RuddonRW, GilmanAG. The pharmacological basis of therapeutics, 9th ed. New York: Pergamon Press, 1995. 122587.
  • 4
    Hirata K, Mukaiya M, Yamamitsu S, Oikawa I, Takashima T, Katsuramaki T, Sasaki K, Denno R, Shirasaka T. Biochemical modulation therapy for pancreatic cancer. J Hepatobiliary Pancreat Surg 1998;5: 25560.
  • 5
    Perez JE, Lacava JA, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH, Romero Acuna LA, Langhi MJ, Romero Acuna JM, Vallejo CT, Leone BA, Machiavelli MR, et al. Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. Am J Oncol 1998;21: 4527.
  • 6
    Scheithauer W, Rosen H, Schiessel R, Schuller M, Karall M, Eenst F, Sebesta CH, Kornek G, Hentschel E, Marczell A, Depisch D. Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil and leucovorin. Cancer 1991;67: 12948.
  • 7
    Sporn JR, Buzaid AC, Slater D, Cohen N, Greenberg BR. Treatment of advanced pancreatic adenocarcinoma with 5-fu, leucovorin, interferon-α-2b and cisplatin. Am J Clin Oncol 1997;20: 813.
  • 8
    Rouger P, Zarba JJ, Dureux M, Basile M, Prignon JP, Mahjoubi M, Benahmed M, Droz JP, Cvitkovic E, Armand JP. Phase-study of cisplatin and 120-hours continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4: 333336.
  • 9
    Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T, Ohashi M, Tateishi K, Shiratori Y, Omata M. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1997;58: 194651.
  • 10
    Inaba M, Sawada H, Hamada H. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. Jpn J Cancer Res 1999;90: 349354.
  • 11
    Kanai F, Shiratori Y, Yoshida Y, Wakimoto H, Hamada H, Kanegae Y, Saito I, Nakabayashi H, Tamaoki T, Lan KH, Kato N, Shiina S, et al. Gene therapy for α-fetoprotein producing human hepatoma cell by adenovirus-mediated transfer of herpes simplex virus thymidine kinase gene. Hepatology 1996;23: 135968.
  • 12
    Rosenfeld ME, Vickers SM, Raben D, Wang M, Sampson L, Feng M, Jaffee E, Curiel DT. Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann Surg 1997;225: 60920.
  • 13
    Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M, Omata M. Tumor-Specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. Gastroenterology 1996;111: 124151.
  • 14
    Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000;105: 116972.
  • 15
    Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johanners A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274: 3736.
  • 16
    Heise C, Sampson JA, Williams A, McCormik F, Von HD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumor efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3: 63945.
  • 17
    Pellegata NS, Sessa F, Bonato M, Leone BE, Solicia E, Ranzani GN. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54: 155660.
  • 18
    Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 1999;11: 22335.
  • 19
    Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSV/GCV suicide gene therapy of cancer, Gene Ther 1999;6: 5762.
  • 20
    Redston MR, Caldas C, Seymour AB, Hruban RH, Costa L, Yeo CJ, Kern SE. p53 Mutation in pancreatic carcinoma and evidence of common involvement of homocopolymer tract in DNA microdeletions. Cancer Res 1994;54: 302533.
  • 21
    Kobari M, Matsuno S, Sato T, Kan M, Tachibana T. Establishment of human pancreatic cancer cell line and detection of pancreatic cancer associated antigen. Tohoku J Exp Med 1984;143: 3346.
  • 22
    Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sakai T, Sugano S, Saito I. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 1995;23: 381621.
  • 23
    Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996;93: 13204.
  • 24
    Moran RG, Spears CS, Heidelberger C. Biochemical determination of tumor sensitivity to 5-fluoruracil:ultrasensitive methods for the determination of 5-fluoro-2-uridylate, 2-deoxyuridylate and thymidylate synthetase. Proc Natl Acad Sci USA 1979;76: 145660.
  • 25
    Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995;55: 38106.
  • 26
    Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 1999;59: 436974.
  • 27
    Lan KH, Kanai F, Shiratori Y, Ohashi M, Tanaka T, Okudaira T, Yoshida Y, Hamada H, Omata M. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res 1997;57: 427984.
  • 28
    McCabe MS, Power JB, Laat MM, Davey MR. Detection of single-copy genes in DNA from transgenic plants by nonradioactive Southern blot analysis. Mol Biotechnol 1997;7: 7984.
  • 29
    Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2-deoxyuridine. Cancer Res 1979;39: 240613.
  • 30
    Sunamura M, Motoi F, Matsuno S. Restricted replication-competent adenovirus: a novel strategy for cancer gene therapy. Int J Clin Oncol 2000;5: 14752.
  • 31
    Heise CC, Williams A, Xue S, Propst M, Kirn DH. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999;59: 26238.
  • 32
    Ganly I, Kirn D, Eckhardt SG, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hof DD, Kaye SB. A phase-study of Onyx-015, an EIB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6: 798806.
  • 33
    Hall AR, Dix BR, O'Carroll SJ, Brethaire AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998;4: 106872.
  • 34
    Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, Macdougall RH, Heise C, Randlev B, Gillenwater AM, et al. A controlled trial of intratumoral ONYX-015, a selectively-replication adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6: 87985.
  • 35
    Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The additional of adenovirus type 5 region e3 enable calydon virus 787 to eliminate distant prostate tumor xenografts, Cancer Res 1999;59: 42003.
  • 36
    Kasuya H, Nishiyama Y, Nomoto S, Hososno J, Takeda S, Nakao A. Intraperitoneal delivery of hrR3 and ganciclovir prolong survival in mice with disseminated pancreatic cancer. J Surg Oncol 1999;72: 13641.